Incidence and case fatality rate of COVID-19 in patients with active epilepsy
OBJECTIVEThis article estimates the incidence and fatality of coronavirus disease 2019 (COVID-19) and identifies potential risk factors for fatality in patients with active epilepsy. METHODSThis is a cross-sectional observational study of patients with active epilepsy and COVID-19. A control group w...
Gespeichert in:
| Veröffentlicht in: | Neurology 2020-09, Vol.95 (10), p.e1417-e1425 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e1425 |
|---|---|
| container_issue | 10 |
| container_start_page | e1417 |
| container_title | Neurology |
| container_volume | 95 |
| creator | Cabezudo-García, Pablo Ciano-Petersen, Nicolás Lundahl Mena-Vázquez, Natalia Pons-Pons, Gracia Castro-Sánchez, María Victoria Serrano-Castro, Pedro J. |
| description | OBJECTIVEThis article estimates the incidence and fatality of coronavirus disease 2019 (COVID-19) and identifies potential risk factors for fatality in patients with active epilepsy.
METHODSThis is a cross-sectional observational study of patients with active epilepsy and COVID-19. A control group was used to compare the cumulative incidence and case-fatality rate (CFR). The main outcomes of the study were cumulative incidence, defined as number of patients with active epilepsy and COVID-19 admitted to an emergency department divided by the total number of patients with epilepsy at risk, and CFR based on the number of deaths during the enrollment period. Multiple logistic regression analysis was performed to investigate risk factors for fatality in patients with active epilepsy.
RESULTSOf the 1,537 patients who fulfilled the inclusion criteria, 21 (1.3%) had active epilepsy. The cumulative incidence (95% confidence interval [CI]) of COVID-19 in patients with epilepsy was higher (1.2% [0.6–2.4]) compared to the population without epilepsy (0.5% [0.5–0.5]). In reverse transcription PCR–positive patients, there were no significant differences in CFR in patients with active epilepsy compared to patients without epilepsy (33.3% vs 8.3%; p = 0.266). Of the 21 patients with active epilepsy, 5 (23%) died. In multivariate analysis, the factor associated with fatality in patients with active epilepsy was hypertension (odds ratio [OR] 2.8 [95% CI 1.3–21.6]). In another model, age (OR 1.0 [95% CI 1.0–1.1]) and epilepsy (OR 5.1 [95% CI 1.3–24.0]) were associated with fatality during hospitalization.
CONCLUSIONCOVID-19 cumulative incidence was higher in patients with active epilepsy. Epilepsy was associated with fatality during hospitalization. Hypertension was associated with fatality in patients with epilepsy. |
| doi_str_mv | 10.1212/WNL.0000000000010033 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2415295302</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2415295302</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5683-9053caada6e797382724ce913397e00a4633f4389e53d0faf02652e373d56c763</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhi1UxC7Qf1AhH3sJjD2xHR_R9oOVFrgU6C1ynYnWJZuksber_fcE7VIkDnQuI42ed0bzMPZJwLmQQl483CzO4bUEAOIBmwoldaZR_vzApgCyyLAwxYQdx_h7hJQ09ohNUCqVG4NTdj1vfaio9cRdW3HvIvHaJdeEtOWDS8S7ms9u7-dfMmF5aHnvUqA2Rb4JacmdT-EvcepDQ33cnrLD2jWRPu77Cbv79vXH7Cpb3H6fzy4XmVe6wMyCQu9c5TQZa7CQRuaerEC0hgBcrhHrHAtLCiuoXQ1SK0losFLaG40n7PNubz90f9YUU7kK0VPTuJa6dSxlPn5qFYIc0XyH-qGLcaC67IewcsO2FFA-iyxHkeVbkWPsbH9h_WtF1b_Qi7kRKHbApmsSDfGxWW9oKJfkmrT83-78negzp4XIMwkSwEIB2ThBgU9I2owl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2415295302</pqid></control><display><type>article</type><title>Incidence and case fatality rate of COVID-19 in patients with active epilepsy</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Cabezudo-García, Pablo ; Ciano-Petersen, Nicolás Lundahl ; Mena-Vázquez, Natalia ; Pons-Pons, Gracia ; Castro-Sánchez, María Victoria ; Serrano-Castro, Pedro J.</creator><creatorcontrib>Cabezudo-García, Pablo ; Ciano-Petersen, Nicolás Lundahl ; Mena-Vázquez, Natalia ; Pons-Pons, Gracia ; Castro-Sánchez, María Victoria ; Serrano-Castro, Pedro J.</creatorcontrib><description>OBJECTIVEThis article estimates the incidence and fatality of coronavirus disease 2019 (COVID-19) and identifies potential risk factors for fatality in patients with active epilepsy.
METHODSThis is a cross-sectional observational study of patients with active epilepsy and COVID-19. A control group was used to compare the cumulative incidence and case-fatality rate (CFR). The main outcomes of the study were cumulative incidence, defined as number of patients with active epilepsy and COVID-19 admitted to an emergency department divided by the total number of patients with epilepsy at risk, and CFR based on the number of deaths during the enrollment period. Multiple logistic regression analysis was performed to investigate risk factors for fatality in patients with active epilepsy.
RESULTSOf the 1,537 patients who fulfilled the inclusion criteria, 21 (1.3%) had active epilepsy. The cumulative incidence (95% confidence interval [CI]) of COVID-19 in patients with epilepsy was higher (1.2% [0.6–2.4]) compared to the population without epilepsy (0.5% [0.5–0.5]). In reverse transcription PCR–positive patients, there were no significant differences in CFR in patients with active epilepsy compared to patients without epilepsy (33.3% vs 8.3%; p = 0.266). Of the 21 patients with active epilepsy, 5 (23%) died. In multivariate analysis, the factor associated with fatality in patients with active epilepsy was hypertension (odds ratio [OR] 2.8 [95% CI 1.3–21.6]). In another model, age (OR 1.0 [95% CI 1.0–1.1]) and epilepsy (OR 5.1 [95% CI 1.3–24.0]) were associated with fatality during hospitalization.
CONCLUSIONCOVID-19 cumulative incidence was higher in patients with active epilepsy. Epilepsy was associated with fatality during hospitalization. Hypertension was associated with fatality in patients with epilepsy.</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0000000000010033</identifier><identifier>PMID: 32554773</identifier><language>eng</language><publisher>United States: American Academy of Neurology</publisher><subject>Adult ; Age Factors ; Aged ; Anticonvulsants - therapeutic use ; Betacoronavirus ; Coronavirus Infections - epidemiology ; Coronavirus Infections - mortality ; COVID-19 ; Cross-Sectional Studies ; Epilepsy - drug therapy ; Epilepsy - epidemiology ; Female ; Hospitalization - statistics & numerical data ; Humans ; Hypertension - epidemiology ; Incidence ; Logistic Models ; Male ; Middle Aged ; Mortality ; Odds Ratio ; Pandemics ; Pneumonia, Viral - epidemiology ; Pneumonia, Viral - mortality ; Risk Factors ; SARS-CoV-2 ; Spain - epidemiology</subject><ispartof>Neurology, 2020-09, Vol.95 (10), p.e1417-e1425</ispartof><rights>American Academy of Neurology</rights><rights>2020 American Academy of Neurology</rights><rights>2020 American Academy of Neurology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5683-9053caada6e797382724ce913397e00a4633f4389e53d0faf02652e373d56c763</citedby><cites>FETCH-LOGICAL-c5683-9053caada6e797382724ce913397e00a4633f4389e53d0faf02652e373d56c763</cites><orcidid>0000-0002-9994-1358 ; 0000-0001-9555-4847 ; 0000-0001-6173-2051 ; 0000-0002-6421-5348 ; 0000-0002-0138-4769 ; 0000-0002-3414-2707</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32554773$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cabezudo-García, Pablo</creatorcontrib><creatorcontrib>Ciano-Petersen, Nicolás Lundahl</creatorcontrib><creatorcontrib>Mena-Vázquez, Natalia</creatorcontrib><creatorcontrib>Pons-Pons, Gracia</creatorcontrib><creatorcontrib>Castro-Sánchez, María Victoria</creatorcontrib><creatorcontrib>Serrano-Castro, Pedro J.</creatorcontrib><title>Incidence and case fatality rate of COVID-19 in patients with active epilepsy</title><title>Neurology</title><addtitle>Neurology</addtitle><description>OBJECTIVEThis article estimates the incidence and fatality of coronavirus disease 2019 (COVID-19) and identifies potential risk factors for fatality in patients with active epilepsy.
METHODSThis is a cross-sectional observational study of patients with active epilepsy and COVID-19. A control group was used to compare the cumulative incidence and case-fatality rate (CFR). The main outcomes of the study were cumulative incidence, defined as number of patients with active epilepsy and COVID-19 admitted to an emergency department divided by the total number of patients with epilepsy at risk, and CFR based on the number of deaths during the enrollment period. Multiple logistic regression analysis was performed to investigate risk factors for fatality in patients with active epilepsy.
RESULTSOf the 1,537 patients who fulfilled the inclusion criteria, 21 (1.3%) had active epilepsy. The cumulative incidence (95% confidence interval [CI]) of COVID-19 in patients with epilepsy was higher (1.2% [0.6–2.4]) compared to the population without epilepsy (0.5% [0.5–0.5]). In reverse transcription PCR–positive patients, there were no significant differences in CFR in patients with active epilepsy compared to patients without epilepsy (33.3% vs 8.3%; p = 0.266). Of the 21 patients with active epilepsy, 5 (23%) died. In multivariate analysis, the factor associated with fatality in patients with active epilepsy was hypertension (odds ratio [OR] 2.8 [95% CI 1.3–21.6]). In another model, age (OR 1.0 [95% CI 1.0–1.1]) and epilepsy (OR 5.1 [95% CI 1.3–24.0]) were associated with fatality during hospitalization.
CONCLUSIONCOVID-19 cumulative incidence was higher in patients with active epilepsy. Epilepsy was associated with fatality during hospitalization. Hypertension was associated with fatality in patients with epilepsy.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Betacoronavirus</subject><subject>Coronavirus Infections - epidemiology</subject><subject>Coronavirus Infections - mortality</subject><subject>COVID-19</subject><subject>Cross-Sectional Studies</subject><subject>Epilepsy - drug therapy</subject><subject>Epilepsy - epidemiology</subject><subject>Female</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Hypertension - epidemiology</subject><subject>Incidence</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Odds Ratio</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Pneumonia, Viral - mortality</subject><subject>Risk Factors</subject><subject>SARS-CoV-2</subject><subject>Spain - epidemiology</subject><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1P3DAQhi1UxC7Qf1AhH3sJjD2xHR_R9oOVFrgU6C1ynYnWJZuksber_fcE7VIkDnQuI42ed0bzMPZJwLmQQl483CzO4bUEAOIBmwoldaZR_vzApgCyyLAwxYQdx_h7hJQ09ohNUCqVG4NTdj1vfaio9cRdW3HvIvHaJdeEtOWDS8S7ms9u7-dfMmF5aHnvUqA2Rb4JacmdT-EvcepDQ33cnrLD2jWRPu77Cbv79vXH7Cpb3H6fzy4XmVe6wMyCQu9c5TQZa7CQRuaerEC0hgBcrhHrHAtLCiuoXQ1SK0losFLaG40n7PNubz90f9YUU7kK0VPTuJa6dSxlPn5qFYIc0XyH-qGLcaC67IewcsO2FFA-iyxHkeVbkWPsbH9h_WtF1b_Qi7kRKHbApmsSDfGxWW9oKJfkmrT83-78negzp4XIMwkSwEIB2ThBgU9I2owl</recordid><startdate>20200908</startdate><enddate>20200908</enddate><creator>Cabezudo-García, Pablo</creator><creator>Ciano-Petersen, Nicolás Lundahl</creator><creator>Mena-Vázquez, Natalia</creator><creator>Pons-Pons, Gracia</creator><creator>Castro-Sánchez, María Victoria</creator><creator>Serrano-Castro, Pedro J.</creator><general>American Academy of Neurology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9994-1358</orcidid><orcidid>https://orcid.org/0000-0001-9555-4847</orcidid><orcidid>https://orcid.org/0000-0001-6173-2051</orcidid><orcidid>https://orcid.org/0000-0002-6421-5348</orcidid><orcidid>https://orcid.org/0000-0002-0138-4769</orcidid><orcidid>https://orcid.org/0000-0002-3414-2707</orcidid></search><sort><creationdate>20200908</creationdate><title>Incidence and case fatality rate of COVID-19 in patients with active epilepsy</title><author>Cabezudo-García, Pablo ; Ciano-Petersen, Nicolás Lundahl ; Mena-Vázquez, Natalia ; Pons-Pons, Gracia ; Castro-Sánchez, María Victoria ; Serrano-Castro, Pedro J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5683-9053caada6e797382724ce913397e00a4633f4389e53d0faf02652e373d56c763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Betacoronavirus</topic><topic>Coronavirus Infections - epidemiology</topic><topic>Coronavirus Infections - mortality</topic><topic>COVID-19</topic><topic>Cross-Sectional Studies</topic><topic>Epilepsy - drug therapy</topic><topic>Epilepsy - epidemiology</topic><topic>Female</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Hypertension - epidemiology</topic><topic>Incidence</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Odds Ratio</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Pneumonia, Viral - mortality</topic><topic>Risk Factors</topic><topic>SARS-CoV-2</topic><topic>Spain - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cabezudo-García, Pablo</creatorcontrib><creatorcontrib>Ciano-Petersen, Nicolás Lundahl</creatorcontrib><creatorcontrib>Mena-Vázquez, Natalia</creatorcontrib><creatorcontrib>Pons-Pons, Gracia</creatorcontrib><creatorcontrib>Castro-Sánchez, María Victoria</creatorcontrib><creatorcontrib>Serrano-Castro, Pedro J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cabezudo-García, Pablo</au><au>Ciano-Petersen, Nicolás Lundahl</au><au>Mena-Vázquez, Natalia</au><au>Pons-Pons, Gracia</au><au>Castro-Sánchez, María Victoria</au><au>Serrano-Castro, Pedro J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence and case fatality rate of COVID-19 in patients with active epilepsy</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2020-09-08</date><risdate>2020</risdate><volume>95</volume><issue>10</issue><spage>e1417</spage><epage>e1425</epage><pages>e1417-e1425</pages><issn>0028-3878</issn><eissn>1526-632X</eissn><abstract>OBJECTIVEThis article estimates the incidence and fatality of coronavirus disease 2019 (COVID-19) and identifies potential risk factors for fatality in patients with active epilepsy.
METHODSThis is a cross-sectional observational study of patients with active epilepsy and COVID-19. A control group was used to compare the cumulative incidence and case-fatality rate (CFR). The main outcomes of the study were cumulative incidence, defined as number of patients with active epilepsy and COVID-19 admitted to an emergency department divided by the total number of patients with epilepsy at risk, and CFR based on the number of deaths during the enrollment period. Multiple logistic regression analysis was performed to investigate risk factors for fatality in patients with active epilepsy.
RESULTSOf the 1,537 patients who fulfilled the inclusion criteria, 21 (1.3%) had active epilepsy. The cumulative incidence (95% confidence interval [CI]) of COVID-19 in patients with epilepsy was higher (1.2% [0.6–2.4]) compared to the population without epilepsy (0.5% [0.5–0.5]). In reverse transcription PCR–positive patients, there were no significant differences in CFR in patients with active epilepsy compared to patients without epilepsy (33.3% vs 8.3%; p = 0.266). Of the 21 patients with active epilepsy, 5 (23%) died. In multivariate analysis, the factor associated with fatality in patients with active epilepsy was hypertension (odds ratio [OR] 2.8 [95% CI 1.3–21.6]). In another model, age (OR 1.0 [95% CI 1.0–1.1]) and epilepsy (OR 5.1 [95% CI 1.3–24.0]) were associated with fatality during hospitalization.
CONCLUSIONCOVID-19 cumulative incidence was higher in patients with active epilepsy. Epilepsy was associated with fatality during hospitalization. Hypertension was associated with fatality in patients with epilepsy.</abstract><cop>United States</cop><pub>American Academy of Neurology</pub><pmid>32554773</pmid><doi>10.1212/WNL.0000000000010033</doi><orcidid>https://orcid.org/0000-0002-9994-1358</orcidid><orcidid>https://orcid.org/0000-0001-9555-4847</orcidid><orcidid>https://orcid.org/0000-0001-6173-2051</orcidid><orcidid>https://orcid.org/0000-0002-6421-5348</orcidid><orcidid>https://orcid.org/0000-0002-0138-4769</orcidid><orcidid>https://orcid.org/0000-0002-3414-2707</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-3878 |
| ispartof | Neurology, 2020-09, Vol.95 (10), p.e1417-e1425 |
| issn | 0028-3878 1526-632X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2415295302 |
| source | MEDLINE; Alma/SFX Local Collection; Journals@Ovid Complete |
| subjects | Adult Age Factors Aged Anticonvulsants - therapeutic use Betacoronavirus Coronavirus Infections - epidemiology Coronavirus Infections - mortality COVID-19 Cross-Sectional Studies Epilepsy - drug therapy Epilepsy - epidemiology Female Hospitalization - statistics & numerical data Humans Hypertension - epidemiology Incidence Logistic Models Male Middle Aged Mortality Odds Ratio Pandemics Pneumonia, Viral - epidemiology Pneumonia, Viral - mortality Risk Factors SARS-CoV-2 Spain - epidemiology |
| title | Incidence and case fatality rate of COVID-19 in patients with active epilepsy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T16%3A41%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20and%20case%20fatality%20rate%20of%20COVID-19%20in%20patients%20with%20active%20epilepsy&rft.jtitle=Neurology&rft.au=Cabezudo-Garc%C3%ADa,%20Pablo&rft.date=2020-09-08&rft.volume=95&rft.issue=10&rft.spage=e1417&rft.epage=e1425&rft.pages=e1417-e1425&rft.issn=0028-3878&rft.eissn=1526-632X&rft_id=info:doi/10.1212/WNL.0000000000010033&rft_dat=%3Cproquest_cross%3E2415295302%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2415295302&rft_id=info:pmid/32554773&rfr_iscdi=true |